ReviewCurrent pharmaceutical biotechnology2018

Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.

Moritz Haaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.